Fate Therapeutics (FATE) PT Raised to $40 at Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Fate Therapeutics (FATE) PT Raised to $45 at Guggenheim
June 10, 2020 7:51 AM EDTGuggenheim analyst Michael Schmidt raised the price target on Fate Therapeutics (NASDAQ: FATE) to $45.00 (from $43.00) while maintaining a Buy rating after the company provided a portfolio-wide clinical update. The update was part of the SEC filings for FATE's capital raise.
Guggenheim... More
Fate Therapeutics (FATE) Prices 6.18M Share Common Offering at $28.31/Sh
June 9, 2020 5:53 AM EDTFate Therapeutics, Inc. (NASDAQ: FATE) today announced the pricing of an underwritten public offering of 6,181,562 shares of its common stock at a public offering price of $28.31 per share, before underwriting discounts, for an aggregate offering of approximately $175 million. Fate Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 927,234 shares of its common stock. The proceeds to Fate Therapeutics from this offering are expected... More
Fate Therapeutics (FATE) Commences Public Offering of Common Stock
June 8, 2020 4:03 PM EDTFate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that it has commenced an underwritten public offering of its common stock. Fate Therapeutics intends to use the net proceeds from the offering to fund clinical trials and nonclinical studies, the manufacture of its clinical product candidates, the expansion of its cGMP compliant manufacturing operations, including the construction,... More
